Zevra Therapeutics logo

Zevra TherapeuticsNASDAQ: ZVRA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 April 2015

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$409.37 M
-8%vs. 3y high
62%vs. sector
-vs. 3y high
-vs. sector
-8%vs. 3y high
94%vs. sector
-24%vs. 3y high
82%vs. sector

Price

after hours | Fri, 25 Oct 2024 22:41:12 GMT
$7.78-$0.07(-0.89%)

Dividend

No data over the past 3 years
$4.45 M$4.87 M
$4.45 M-$19.93 M

Analysts recommendations

Institutional Ownership

ZVRA Latest News

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
globenewswire.com10 October 2024 Sentiment: POSITIVE

CELEBRATION, Fla., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will participate in a Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC on Thursday, October 17, 2024 at 2 p.m. ET.

Zevra Stock Surges Close to 70% in 3 Months: Here's Why
zacks.com04 October 2024 Sentiment: POSITIVE

The FDA approval for ZVRA's Miplyffa (arimoclomol) capsules in September for treating Niemann-Pick disease type C drives the stock.

Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?
zacks.com25 September 2024 Sentiment: NEUTRAL

Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024
globenewswire.com24 September 2024 Sentiment: POSITIVE

KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase 3 study CELEBRATION, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a commercial-stage rare disease therapeutics company, today announced that Rene Braeckman, Ph.D.

Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
globenewswire.com20 September 2024 Sentiment: POSITIVE

MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
globenewswire.com06 September 2024 Sentiment: POSITIVE

New clinical efficacy and safety data for arimoclomol as a possible treatment for Niemann-Pick disease type C, including from long-term and real-world settings, demonstrate clinically meaningful reduction in disease progression

Zevra Therapeutics to Participate at Upcoming Investor Conferences
globenewswire.com29 August 2024 Sentiment: POSITIVE

CELEBRATION, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will present at upcoming investor conferences during the month of September 2024. Additionally, management will be available for one-on-one meetings with registered attendees at each conference.

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
zacks.com13 August 2024 Sentiment: NEUTRAL

Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.15 per share a year ago.

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock
globenewswire.com09 August 2024 Sentiment: POSITIVE

CELEBRATION, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a rare disease therapeutics company (“Zevra”), today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at an offering price of $6.50 per share, for total gross proceeds of approximately $60.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Zevra. All of the common stock is being offered by Zevra. The offering is expected to close on August 12, 2024, subject to customary closing conditions. In addition, Zevra has granted the underwriters a 30-day option to purchase up to an additional 1,384,615 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Zevra Therapeutics Announces Proposed Public Offering of Common Stock
globenewswire.com08 August 2024 Sentiment: POSITIVE

CELEBRATION, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a rare disease therapeutics company (“Zevra”), today announced the commencement of a proposed underwritten public offering of its common stock. All shares of common stock to be sold in the proposed offering will be sold by Zevra. Zevra also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • 1(current)

What type of business is Zevra Therapeutics?

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

What sector is Zevra Therapeutics in?

Zevra Therapeutics is in the Healthcare sector

What industry is Zevra Therapeutics in?

Zevra Therapeutics is in the Biotechnology industry

What country is Zevra Therapeutics from?

Zevra Therapeutics is headquartered in United States

When did Zevra Therapeutics go public?

Zevra Therapeutics initial public offering (IPO) was on 16 April 2015

What is Zevra Therapeutics website?

https://zevra.com

Is Zevra Therapeutics in the S&P 500?

No, Zevra Therapeutics is not included in the S&P 500 index

Is Zevra Therapeutics in the NASDAQ 100?

No, Zevra Therapeutics is not included in the NASDAQ 100 index

Is Zevra Therapeutics in the Dow Jones?

No, Zevra Therapeutics is not included in the Dow Jones index

When was Zevra Therapeutics the previous earnings report?

No data

When does Zevra Therapeutics earnings report?

The next expected earnings date for Zevra Therapeutics is 07 November 2024